Research Article
Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?
Table 1
Patient, tumor, and treatment characteristics in the entire cohort and according to use of statin and ASA.
| | Characteristics | Entire cohort
() | No statin/ASA
() | Statin, no ASA
() | ASA, no statin
() | Statin + ASA
() |
| | Median age | 71 yrs | 71 yrs | 71 yrs | 72 yrs | 72 yrs |
| | Charlson comorbidity index | | | | | | | 0 | 65% (2507) | 73% (1773) | 51% (260) | 62% (313) | 40% (161) | | 1 | 25% (961) | 20% (473) | 33% (166) | 29% (145) | 43% (177) | | ≥2 | 10% (383) | 7.5% (182) | 16% (80) | 10% (51) | 17% (70) |
| | Low risk | 14% (563) | 14% (334) | 15% (80) | 14% (72) | 17% (69) |
| | Intermediate risk | 39% (1534) | 37% (900) | 40% (201) | 46% (236) | 45% (182) |
| | High risk | 44% (1718) | 47% (1141) | 33% (217) | 38% (191) | 36% (146) |
| | Null risk | 2% (83) | 2% (53) | 2% (8) | 2% (10) | 2% (11) |
| Radiation dose Gy
aMedian (range) | 70 Gy (50–80 Gy) | 70 Gy (52.50–78 Gy) | 70 Gy (52.50–78 Gy) | 70 Gy (52.50–78 Gy) | 70 Gy (52.50–78 Gy) |
| Radiation dose BED1.5
aMedian (range) | 163 (126–201) | 163 (126–201) | 163 (133–201) | 163 (128–195) | 163 (140–182) |
| | Frequency ADTb use | 67% | 71% | 61% | 63% | 59% |
| | Mean duration ADT² (if used) | 16 mo | 18 mo | 18 mo | 18 mo | 1 mo |
|
|
RT: radiation therapy; bADT: androgen deprivation therapy.
|
